Flecainide is not a beta blocker. It belongs to a completely different drug class called Class IC antiarrhythmics. While both flecainide and beta blockers treat irregular heart rhythms, they work through entirely different mechanisms in the heart.
How Flecainide Actually Works
Flecainide’s primary job is blocking sodium channels in heart muscle cells. These sodium channels (called Nav1.5) are responsible for the electrical signals that trigger each heartbeat. By slowing down sodium flow into heart cells, flecainide reduces the speed at which electrical impulses travel through the heart. This makes it harder for abnormal, rapid rhythms to sustain themselves.
The drug is particularly effective in the upper chambers of the heart (the atria), where it slows electrical conduction more than in the lower chambers. This property makes it especially useful for treating atrial fibrillation and other rhythm problems that originate in the atria.
How Beta Blockers Differ
Beta blockers work on an entirely different system. Instead of targeting sodium channels, they block the effects of adrenaline on the heart by sitting on beta-adrenergic receptors. This slows the heart rate, lowers blood pressure, and reduces the heart’s workload. Common beta blockers include metoprolol, atenolol, and propranolol.
In the standard classification system for heart rhythm drugs (the Vaughan-Williams system), beta blockers fall into Class II, while flecainide is Class IC. The distinction matters because these classes carry different risks, different benefits, and different rules about who can safely take them.
Why Doctors Often Prescribe Both Together
Even though flecainide isn’t a beta blocker, you may be prescribed both at the same time. This is common practice, and there’s a specific reason for it. Flecainide can sometimes organize a chaotic rhythm like atrial fibrillation into a more regular but still abnormal pattern called atrial flutter. In rare cases, that flutter can conduct very rapidly to the lower chambers of the heart, potentially causing a dangerously fast heartbeat.
Adding a beta blocker acts as a safety net. The beta blocker slows conduction between the upper and lower chambers, preventing that rapid transmission. Research published in EP Europace found that combining flecainide with the beta blocker metoprolol reduced atrial fibrillation recurrences and improved tolerability over one year. The beta blocker’s adrenaline-dampening effects also appear to counteract some of flecainide’s potential to provoke new rhythm problems, making the combination safer than flecainide alone for many patients.
What Flecainide Treats
Flecainide is most commonly prescribed for paroxysmal atrial fibrillation (episodes that come and go) and paroxysmal supraventricular tachycardia, a type of rapid heartbeat originating above the ventricles. It can also be used for sustained ventricular tachycardia, a more serious rhythm disorder in the lower chambers. Starting doses are typically 50 mg twice daily for atrial conditions and 100 mg twice daily for ventricular tachycardia, with a maximum of 400 mg per day.
Important Safety Restrictions
Flecainide carries a safety restriction that beta blockers generally do not: it should not be used in people with structural heart disease or a history of heart attack. This rule dates back to 1991, when a landmark trial called CAST tested whether suppressing extra heartbeats after a heart attack would save lives. The trial enrolled nearly 1,500 patients and had to be stopped early because those taking flecainide or a similar drug had higher death rates than those on placebo.
Current European and American guidelines still contraindicate flecainide in coronary artery disease and structural heart conditions. One narrow exception exists: in a genetic condition called arrhythmogenic right ventricular cardiomyopathy, flecainide can be considered alongside beta blockers when other treatments haven’t controlled symptoms.
Monitoring While Taking Flecainide
Because flecainide slows electrical conduction, it widens a specific part of the heart’s electrical tracing on an ECG called the QRS complex. Doctors monitor this widening carefully. Research in Heart Rhythm found that QRS widening correlates closely with reduced pumping strength in the heart’s main chamber. If the QRS complex widens too much, it signals that the dose needs to be lowered. This kind of ECG monitoring isn’t typically required with beta blockers, which is another practical difference between the two drug classes.
If you’re taking flecainide and wondering whether it replaces a beta blocker or vice versa, the short answer is that it doesn’t. They target different parts of the heart’s electrical and hormonal systems, carry different risks, and are often used as partners rather than substitutes.